Journal
ACS INFECTIOUS DISEASES
Volume 1, Issue 6, Pages 234-242Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.5b00003
Keywords
Mycobacterium tuberculosis; beta-lactamase inhibition; boronic acid transitional state inhibitors; acylation high-energy intermediate; deacylation high-energy intermediate; cefoperazone analogue EC19
Categories
Funding
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI100560, R01AI063517]
- NIH [AI060899]
- Cleveland Department of Veterans Affairs, Veterans Affairs Merit Review Program Award [1I01BX001974]
- Geriatric Research Education and Clinical Center VISN 10
Ask authors/readers for more resources
BlaC, the single chromosomally encoded beta-lactamase of Mycobacterium tuberculosis, has been identified as a promising target for novel therapies that rely upon beta-lactamase inhibition. Boronic acid transition state inhibitors (BATSIs) are a class of beta-lactamase inhibitors which permit rational inhibitor design by combinations of various R1 and R2 side chains. To explore the structural determinants of effective inhibition, we screened a panel of 25 BATSIs to explore key structure function relationships. We identified a cefoperazone analogue, EC19, which displayed slow, time dependent inhibition against BlaC with a potency similar to that of clavulanate (K-i* of 0.65 +/- 0.05 mu M). To further characterize the molecular basis of inhibition, we solved the crystallographic structure of the EC19-BlaC(N172A) complex and expanded our analysis to variant enzymes. The results of this structure function analysis encourage the design of a novel class of beta-lactamase inhibitors, BATSIs, to be used against Mycobacterium tuberculosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available